INS and diabetes mellitus: Price et al. stated that during high doses of ICS therapy (500 μg/day or greater fluticasone propionate equivalent), there is a statistically significant risk of SID development, progression of diabetes mellitus, and the necessity of modifying diabetes treatment with an insulin introduction [73].